Regulus shares spike on a high success rate for RG-101 hep C combos

John Carroll Can Regulus still make a splash in the increasingly crowded hepatitis C drug market? The biotech says yes, backing up its case for RG-101 with interim Phase II data that ...

Does pharma need to get cracking on Instagram? New features could be the trigger

Tracy Staton Instagram's latest updates could help pharma companies get more out of using the social app. Longer videos, for instance, give more room for drugmakers to comply with ...

Pfizer pulls thousands of bottles of children’s and infants’ Advil in Canada

Eric Palmer Parents needing to treat their children during this cold season are facing another hurdle after Pfizer pulled 126 lots of children's and infants' Advil products ...

Survey: Biopharma gets a bad grade on gender diversity

John Carroll The biopharma industry doesn't do a very good job when it comes down to the way it handles gender diversity. And if you're a woman in this business, chances are ...

UPDATED: A patient in Akashi’s suspended Duchenne MD trial dies

John Carroll A little more than a week after Cambridge, MA-based Akashi Therapeutics suspended its study of a new drug for Duchenne muscular dystrophy after a patient was sent to the ...

EMA: Faulty device didn’t distort study findings for Bayer’s Xarelto

Carly Helfand Last December, European regulators said they were no longer sure whether results from a trial of Bayer's new-age clot-buster Xarelto were accurate ...

Follow-on bonanza drives U.K. investment in life science stocks past £1B

Nick Paul Taylor At first glance, 2015 looks like the year the London Stock Exchange turned its back on biotech once again. Acacia Pharma and Shield Therapeutics both tried and failed ...

Can fast-growing Eliquis overtake J&J’s Xarelto? Bristol’s execs think so

Carly Helfand Eliquis, a new-age anticoagulant that once dragged well behind analysts' expectations, has rocketed to the top of Bristol-Myers Squibb's sales charts. And company ...

U.K. keeps funding for clinical research sites flat through to 2022

Nick Paul Taylor The United Kingdom government is to pump £112 million ($ 160 million) into a network of clinical research facilities from 2017 to 2022. Officials see the investment ...

Backed by a lineup of marquee VCs, Unity Biotechnology tackles the hard science of aging

John Carroll Imagine a drug that could clear away "senescent" cells and make the life span allotted to you healthier, absent many of the myriad diseases that can accumulate ...

Merck treads water in Q4 as Keytruda helps offset Remicade suffering

Tracy Staton Merck & Co. took a one-two punch in the fourth quarter. Revenue from two top-selling franchises–Januvia and Remicade–slid, dragging overall ...

Proteostasis and AveXis test the troubled IPO waters as biotech valuations wane

Damian Garde A pair of early-stage biotech companies has joined the thinning queue of drug developers trying to go public amid a painful market correction, angling to raise more than ...
Page 1 of 212
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS